<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403765</url>
  </required_header>
  <id_info>
    <org_study_id>SMN01</org_study_id>
    <nct_id>NCT02403765</nct_id>
  </id_info>
  <brief_title>Diagnostic Tools for Parkinson's Disease</brief_title>
  <official_title>Realization of Diagnostic Tools for the Early Analysis of Parkinson's Disease Through the Identification of Genetic Risk Profiles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to identify genetic variants associated to Parkinson's disease through the
      analysis of exome-sequencing data of familial cases and controls. The identified variants
      will be used to generate a diagnostic tool for the identification of genetic risk profiles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Clinical evaluation of PD patients and relatives

        2. High throughput analysis of genetic variants in genome exomes

        3. Genotype-phenotype association testing

        4. Identification of genetic risk variants for PD
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genetic variants associated with Parkinson's disease</measure>
    <time_frame>Two years</time_frame>
    <description>Analysis of exome sequencing data; annotation of genetic variants; selection of variants present in cases and absent in controls</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Family cases</arm_group_label>
    <description>Family-based Parkinson patients carrying genetic variants associated with the disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Family controls</arm_group_label>
    <description>Family-based Control subjects</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for DNA extraction
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be selected from the Center for Parkinson's disease of the IRCCS Neuromed,
        according to specific inclusion criteria. Approximatey 500 subjects, 30 years of age or
        older, recruited with a family-based approach, will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of at least two out the following cardinal signs: resting tremor, cogwheel
             rigidity, bradykinesia, asymmetrical onset of symptoms and symptomatic response to
             L-dopa (levodopa)

        Exclusion Criteria:

          -  Previous thalamotomy on the implanted sided, significant brain atrophy or structural
             damage seen on CT or MRI, marked cognitive dysfunction, active psychiatric symptoms,
             or concurrent neurological or other uncontrolled medical disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Simeone</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Neuromed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Antonio Simeone</investigator_full_name>
    <investigator_title>Head</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

